GlassScriptPhysician profile
Nora L Walker
NPI 1104823822
$9,432.98
in general payments reported to CMS, 2019-2025
31 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $917 · 2021: $1,215 · 2022: $949 · 2023: $1,628 · 2024: $1,381 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,954 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,953.69 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,890.55 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,342.47 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $940.82 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.08 | 2019-2024 | Ofev |
| Harmony Biosciences LLC | $449.61 | 2021-2025 | Wakix |
| Mylan Specialty L.P. | $436.74 | 2019-2024 | Yupelri |
| Abiomed | $282.06 | 2022-2023 | Impella |
| Paratek Pharmaceuticals, INC. | $269.19 | 2019-2023 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $266.69 | 2020-2025 | Dupixent |
| Philips North America LLC | $222.43 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $194.07 | 2024-2025 | Acthar |
| Verona Pharma, INC. | $182.68 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $159.07 | 2024-2025 | Tyvaso, Tyvaso |
| Inari Medical, INC. | $145.71 | 2022 | |
| Genzyme Corporation | $138.87 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $125.00 | 2024 | Sunosi |
| Electromed, INC. | $100.77 | 2024-2025 | Smartvest |
| Baxter Healthcare | $87.67 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Abbvie INC. | $76.81 | 2022-2025 | Avycaz |
| Advanced Respiratory, INC | $76.65 | 2020-2021 | |
| Gilead Sciences, INC. | $67.63 | 2019-2023 | Veklury |
| Eisai INC. | $61.43 | 2021 | |
| Merck Sharp & Dohme LLC | $53.09 | 2019-2020 | |
| Grifols USA, LLC | $46.44 | 2025 | Prolastin-C Liquid |
| Insmed, INC. | $42.68 | 2024-2025 | Brinsupri, Arikayce |
| Melinta Therapeutics, LLC | $33.36 | 2022-2023 | Vabomere |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2019 | |
| Itamar Medical INC | $17.15 | 2023 | Watchpatone |
| Fisher & Paykel Healthcare INC | $16.07 | 2025 | Fisher & Paykel Healthcare |
| Alexion Pharmaceuticals, INC. | $15.35 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.